Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer
作者： Bodvaël Pennarun , Annemieke Meijer , Elisabeth G.E. de Vries , Jan H. Kleibeuker , Frank Kruyt
DOI: 10.1016/J.BBCAN.2009.11.004
关键词:
摘要: … sphingolipid ceramide in the outer leaflet of the cell membrane, initiating formation of ceramide… The reversible attachment of a palmitate to a cysteine residue, a process also known as S-…
core.ac.uk
narcis.nl
elsevier.com参考文章(243)
Thomas T.Y. Wang, Jiingjau Jeng, Coordinated regulation of two TRAIL-R2/KILLER/DR5 mRNA isoforms by DNA damaging agents, serum and 17β-estradiol in human breast cancer cells Breast Cancer Research and Treatment. ,vol. 61, pp. 87- 96 ,(2000) , 10.1023/A:1006432201432
Christina Falschlehner, Christoph H. Emmerich, Björn Gerlach, Henning Walczak, TRAIL signalling: decisions between life and death. The International Journal of Biochemistry & Cell Biology. ,vol. 39, pp. 1462- 1475 ,(2007) , 10.1016/J.BIOCEL.2007.02.007
Sun-Mi Park, Robert Schickel, Marcus E Peter, Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Current Opinion in Cell Biology. ,vol. 17, pp. 610- 616 ,(2005) , 10.1016/J.CEB.2005.09.010
Lisa M. Butler, Vasilios Liapis, Stelios Bouralexis, Katie Welldon, Shelley Hay, Le M. Thai, Agatha Labrinidis, Wayne D. Tilley, David M. Findlay, Andreas Evdokiou, The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL International Journal of Cancer. ,vol. 119, pp. 944- 954 ,(2006) , 10.1002/IJC.21939
Avi Ashkenazi, Targeting death and decoy receptors of the tumour-necrosis factor superfamily Nature Reviews Cancer. ,vol. 2, pp. 420- 430 ,(2002) , 10.1038/NRC821
Fiona C KIMBERLEY, Gavin R SCREATON, Following a TRAIL: update on a ligand and its five receptors. Cell Research. ,vol. 14, pp. 359- 372 ,(2004) , 10.1038/SJ.CR.7290236
M Garofalo, C Quintavalle, G Di Leva, C Zanca, G Romano, C Taccioli, C G Liu, C M Croce, G Condorelli, MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene. ,vol. 27, pp. 3845- 3855 ,(2008) , 10.1038/ONC.2008.6
Vicente Tur, Almer M. van der Sloot, Carlos R. Reis, Eva Szegezdi, Robbert H. Cool, Afshin Samali, Luis Serrano, Wim J. Quax, DR4-selective Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Variants Obtained by Structure-based Design Journal of Biological Chemistry. ,vol. 283, pp. 20560- 20568 ,(2008) , 10.1074/JBC.M800457200
Klaus W Wagner, Elizabeth A Punnoose, Thomas Januario, David A Lawrence, Robert M Pitti, Kate Lancaster, Dori Lee, Melissa von Goetz, Sharon Fong Yee, Klara Totpal, Ling Huw, Viswanatham Katta, Guy Cavet, Sarah G Hymowitz, Lukas Amler, Avi Ashkenazi, Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL Nature Medicine. ,vol. 13, pp. 1070- 1077 ,(2007) , 10.1038/NM1627
Jacob M. Estes, Patsy G. Oliver, J. Michael Straughn, Tong Zhou, Wenquan Wang, William E. Grizzle, Ronald D. Alvarez, Cecil R. Stockard, Albert F. LoBuglio, Donald J. Buchsbaum, Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model Gynecologic Oncology. ,vol. 105, pp. 291- 298 ,(2007) , 10.1016/J.YGYNO.2006.12.033